1. Home
  2. PK vs ZLAB Comparison

PK vs ZLAB Comparison

Compare PK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PK
    SELLHOLDBUYas of 19 hours ago
  • ZLAB
    SELLHOLDBUYas of 19 hours ago
  • Stock Information
  • Founded
  • PK 1946
  • ZLAB 2013
  • Country
  • PK United States
  • ZLAB China
  • Employees
  • PK N/A
  • ZLAB N/A
  • Industry
  • PK Real Estate Investment Trusts
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • PK Real Estate
  • ZLAB Health Care
  • Exchange
  • PK Nasdaq
  • ZLAB Nasdaq
  • Market Cap
  • PK 3.0B
  • ZLAB 3.0B
  • IPO Year
  • PK N/A
  • ZLAB 2017
  • Fundamental
  • Price
  • PK $14.86
  • ZLAB $26.72
  • Analyst Decision
  • PK Buy
  • ZLAB Strong Buy
  • Analyst Count
  • PK 13
  • ZLAB 3
  • Target Price
  • PK $18.79
  • ZLAB $55.00
  • AVG Volume (30 Days)
  • PK 3.0M
  • ZLAB 748.2K
  • Earning Date
  • PK 10-29-2024
  • ZLAB 11-12-2024
  • Dividend Yield
  • PK 6.72%
  • ZLAB N/A
  • EPS Growth
  • PK N/A
  • ZLAB N/A
  • EPS
  • PK 1.57
  • ZLAB N/A
  • Revenue
  • PK $2,662,000,000.00
  • ZLAB $355,748,000.00
  • Revenue This Year
  • PK N/A
  • ZLAB $48.50
  • Revenue Next Year
  • PK $4.04
  • ZLAB $47.37
  • P/E Ratio
  • PK $9.48
  • ZLAB N/A
  • Revenue Growth
  • PK N/A
  • ZLAB 35.01
  • 52 Week Low
  • PK $13.24
  • ZLAB $13.48
  • 52 Week High
  • PK $18.05
  • ZLAB $36.60
  • Technical
  • Relative Strength Index (RSI)
  • PK 45.99
  • ZLAB 46.04
  • Support Level
  • PK $14.34
  • ZLAB $25.71
  • Resistance Level
  • PK $15.57
  • ZLAB $27.49
  • Average True Range (ATR)
  • PK 0.44
  • ZLAB 1.07
  • MACD
  • PK -0.15
  • ZLAB -0.17
  • Stochastic Oscillator
  • PK 27.25
  • ZLAB 21.54

Stock Price Comparison Chart: PK vs ZLAB

PK
ZLAB
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober020406080100120140160180200PK VS ZLAB

About PK Park Hotels & Resorts Inc.

Park Hotels & Resorts owns upper-upscale and luxury hotels with 23,428 rooms across 39 hotels in the United States. Park also has interests through joint ventures in another 2,665 rooms in four U.S. hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality U.S. hotels to focus on high-quality assets in domestic gateway markets.

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use